Abstract: Apparatus and processes to grow a biomaterial made of aerial mycelium by sensing and controlling airborne mist concentration, regardless of relative humidity. A growth matrix comprising a growth medium and a fungus, is grown under controlled environmental conditions to produce a mycelium product. To control growth conditions precisely and efficiently, airborne mist is electronically detected using one or more sensors, configured to measure airborne mist concentration visually, optically, chemically, electromagnetically, or by laser, ultrasonically, with radar, or other means. Electronic detection of airborne mist using one or more sensors generates a signal that is transmitted to a processor that can either maintain, increase, or decrease airborne mist concentration in a growth environment. The present invention provides processes of growing mycelium that are repeatable and resource efficient, while providing high quality and quantity mycelium-based products.

Abstract: A system is provided for informing a therapeutic procedure. In some embodiments, the system may be configured to determine specific states associated with a sleep-wake cycle of a patient. Additionally, the system may be configured to measure one or more signals with cardiac activity of the patient upon detecting the specific states of the sleep-wake cycle of the patient. Subsequently, the system may be configured to determine one or more parameters for applying an electrical signal to an anatomical element of the patient based on the one or more signals with cardiac activity. In some embodiments, the system may be configured to establish a longitudinal trend of cardiac metrics for the patient based on a plurality of signals with cardiac activity for the patient measured during the specific states of the sleep-wake cycle across a plurality of days.

Abstract: Systems and methods for generating and/or applying an adjustment for one or more parameters of a neuromodulation therapy of a user are provided. One or more physiological-based inputs of the user may be received and a therapy response score may be determined based on the one or more physiological-based inputs. At least one adjustment for one or more parameters of the neuromodulation therapy may be generated based on the therapy response score.

Abstract: A system is provided for identifying and reducing noise in a therapeutic procedure. For example, the system may be configured to measure one or more signals with cardiac activity. The system may be configured to then identify one or more sources of noise that are distorting the one or more signals with cardiac activity and may reduce the one or more sources of noise from the one or more signals with cardiac activity. Subsequently, the system may be configured to determine one or more aggregate cardiac-derived metrics and/or save processed cardiac data based on the one or more signals with cardiac activity with the one or more sources of noise reduced. Additionally, the system may be configured to determine one or more parameters for applying an electrical signal to an anatomical element of a patient based on the one or more aggregate cardiac-derived metrics and/or saved processed cardiac data.

Abstract: The invention relates to a cementing tool for use in oil and gas well decommissioning operations, in particular so called perforate, wash and cement procedures. The tool (1) is designed for running in a well on drill string and for jetting cement through previously formed perforations in the casing (10) to fill the outer annulus (9) with cement. The tool (1) has a cylindrical wall (3) which is formed from steel (11) and elastomeric (5) elements, whereby it is expandable between a first diameter in which it may be run down the well and a second, larger diameter deployed during cementing operations. (FIG. 2).

Abstract: Methods are disclosed for generating aerial mycelium, such as mycological material comprising solely mycelia from depleted substrate or depleted and rejuvenated substrate. Alternatively, methods are disclosed for generating mycelia and mushrooms from depleted substrate or depleted and rejuvenated substrate. Alternative methods are disclosed for generating differentiated mycelium materials using depleted substrate or depleted and rejuvenated substrate. The mycelia products that are generated can be used in the food industry (e.g., as a meat analog) and in other industries, such as textiles, packaging, and others. The present invention provides systems and methods for generating mycelia that are repeatable and energy efficient, while providing consistently high quality and quantity mycelium-based products.

Abstract: The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.

Abstract: The present invention relates to a SBDS inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SBDS inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SBDS and capable of reducing the level of a SBDS mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.

Abstract: The present invention relates to a SEPT9 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SEPT9 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SEPT9 and capable of reducing the level of a SEPT9 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.

Abstract: The present invention relates to a COPS3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of COPS3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to COPS3 and capable of reducing the level of a COPS3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.

Abstract: The present invention relates to a SCAMP3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SCAMP3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SCAMP3 and capable of reducing the level of a SCAMP3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.

Abstract: The present invention relates to a SARAF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of SARAF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to SARAF and capable of reducing the level of a SARAF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.

Abstract: The invention describes a methodology for production of a secondary extra-particle fungal matrix for application as a mycological material, manufactured via a Type II actively aerated static packed-bed bioreactor. A pre-conditioned air stream is passed through a substrate of discrete elements inoculated with a filamentous fungus to form an isotropic inter-particle hyphal matrix between the discrete elements. Continued feeding of the air through the substrate of discrete elements and isotropic inter-particle hyphal matrixes develops an extra-particle hyphal matrix that extends from an isotropic inter-particle hyphal matrix in the direction of airflow into a void space within the vessel.

Abstract: The process for producing mycelium biomaterial provides fresh oxygen to the growing mycelium biomaterial while removing waste heat and waste carbon dioxide by forced aeration through large volumes of material. In a first phase of fungal expansion, humidified air at a programmed temperature is passed upwardly and through a fungal inoculated substrate of discrete particles to allow the fungal inoculum to expand and dominate the substrate. Nutrient is added to the inoculated mixture and a second phase of fungal expansion is performed wherein humidified air at a programmed temperature is passed upwardly and through the nutrient enriched fungal inoculated substrate to allow the fungal inoculum to bond the discrete particles into a self-supporting biocomposite. The process and apparatus of the invention allows for the processing of grown materials bound by mycelium at depths of greater than 6? and particularly in the range of from 24? to 28?.

Abstract: An improved mycelium in the form of an edible aerial mycelium that is suitable for use as a food product, including a food ingredient for making mycelium-based food, such as bacon. A method of making an edible aerial mycelium suitable for use as a food product, including a food ingredient. An edible product containing an edible aerial mycelium, and a method of making an edible product comprising an edible aerial mycelium, such as a mycelium-based bacon. A mycelium-based food product having a texture that is analogous to a whole-muscle meat product, wherein that whole-muscle meat product is bacon.

Abstract: This application relates generally to aerial mycelium and methods of making aerial mycelium suitable for use as a food or textile product or ingredient. Such a food product or ingredient can include edible aerial mycelium having a texture that is analogous to a whole-muscle meat product, such as for example mycelium-based bacon. Such a textile product or ingredient can be used in the manufacture of mycelium-based textile products, leather-like materials, petroleum-based product alternatives, or foams.

Abstract: The invention describes a methodology for production of a secondary extra-particle fungal matrix for application as a mycological material, manufactured via a Type II actively aerated static packed-bed bioreactor. A pre-conditioned air stream is passed through a substrate of discrete elements inoculated with a filamentous fungus to form an isotropic inter-particle hyphal matrix between the discrete elements. Continued feeding of the air through the substrate of discrete elements and isotropic inter-particle hyphal matrixes develops an extra-particle hyphal matrix that extends from an isotropic inter-particle hyphal matrix in the direction of airflow into a void space within the vessel.

Abstract: The process for producing mycelium biomaterial provides fresh oxygen to the growing mycelium biomaterial while removing waste heat and waste carbon dioxide by forced aeration through large volumes of material. In a first phase of fungal expansion, humidified air at a programmed temperature is passed upwardly and through a fungal inoculated substrate of discrete particles to allow the fungal inoculum to expand and dominate the substrate. Nutrient is added to the inoculated mixture and a second phase of fungal expansion is performed wherein humidified air at a programmed temperature is passed upwardly and through the nutrient enriched fungal inoculated substrate to allow the fungal inoculum to bond the discrete particles into a self-supporting biocomposite. The process and apparatus of the invention allows for the processing of grown materials bound by mycelium at depths of greater than 6? and particularly in the range of from 24? to 28?.

Abstract: Generating ferrate ex situ by activating persulfate with BOF steel slag fines and/or ferric iron. A persulfate solution flows therethrough or thereover the BOF steel slag within, for example, a filter, fluidized bed or continuously stirred tank reactor. The ex situ generation will produce a leachate that contains multiple reactive oxidant species (ROS) such as hydrogen peroxide (H2O2), superoxide (O2.), sulfate radicals, hydroxyl radicals (OH.) and uniquely ferrate species including Fe IV, V and VI. These ROS will destroy organic compounds, sterilize, and can oxidize inorganics and a wide range of targeted contaminants in distressed water (e.g., drinking water, process water, wastewater, industrial process streams/waters, municipal process streams/waters, landfill leachate, sewage/septic systems, bilge waters, drilling fluids, mine effluents).

Abstract: A method for controlling xylophages (e.g., termites, Asian Beetle, Emerald Ash borer, Weevils, Deathwatch Caterpillars, cockroaches) by inhibiting methane production of methanogenic Archaea in the digestive tract thereof. The inhibiting of the critical biochemical pathways specific to the methanogenic Archaea is achieved by contacting the xylophage with one or more antimethanogenic reagent (AMR) compounds. The AMRs may include, for example, naturally-occurring statins (which may be found in red yeast rice) or derivatives thereof, linoleic acid or related compounds, essential oils, certain synthetic compounds or combinations thereof. As a result, the effectiveness of the methanogenic Archaea to produce methane is compromised. This subsequently results into the malfunctioning of the xylophages' digestive system and provides a safe, natural, green and sustainable means of controlling the xylophages.